Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Cumberland Pharmaceuticals (CPIX) over the last 17 years, with Q3 2025 value amounting to $34.1 million.

  • Cumberland Pharmaceuticals' Total Non-Current Liabilities fell 2606.97% to $34.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $34.1 million, marking a year-over-year decrease of 2606.97%. This contributed to the annual value of $46.7 million for FY2024, which is 146.54% up from last year.
  • As of Q3 2025, Cumberland Pharmaceuticals' Total Non-Current Liabilities stood at $34.1 million, which was down 2606.97% from $33.9 million recorded in Q2 2025.
  • Over the past 5 years, Cumberland Pharmaceuticals' Total Non-Current Liabilities peaked at $49.4 million during Q4 2022, and registered a low of $33.2 million during Q2 2021.
  • In the last 5 years, Cumberland Pharmaceuticals' Total Non-Current Liabilities had a median value of $44.6 million in 2022 and averaged $41.8 million.
  • Its Total Non-Current Liabilities has fluctuated over the past 5 years, first surged by 4363.57% in 2022, then crashed by 2616.21% in 2025.
  • Quarter analysis of 5 years shows Cumberland Pharmaceuticals' Total Non-Current Liabilities stood at $34.4 million in 2021, then skyrocketed by 43.64% to $49.4 million in 2022, then dropped by 6.69% to $46.1 million in 2023, then grew by 1.47% to $46.7 million in 2024, then fell by 26.94% to $34.1 million in 2025.
  • Its last three reported values are $34.1 million in Q3 2025, $33.9 million for Q2 2025, and $35.6 million during Q1 2025.